Understanding oncogenic signaling pathways is essential in unraveling the mechanisms of tumor development and progression. The aberrant activation of pathways such as PI3K/AKT, RAS/RAF/MEK/ERK, and JAK/STAT supports uncontrolled cell growth, survival, and metastasis. Recent advances in molecular oncology have unraveled critical regulatory nodes in such networks, providing novel opportunities for targeted therapeutic intervention. Small-molecule inhibitors, monoclonal antibodies, and pathway-specific modulators are reshaping cancer treatment, enabling targeted, precision-based approaches that reduce toxicity and improve efficacy.

This scientific session, at the Cancer Research and Development Conference 2026, will discuss how disruptions in these signaling cascades lead to the initiation of tumors and their eventual resistance to therapy. Experts will review current breakthroughs in pathway-targeted drug design, mechanisms of resistance, and strategies for combination therapies. Emerging biomarkers guiding patient selection and treatment optimization will also be explored. Join us to delve into the dynamic landscape of oncogenic signaling and explore how pathway-focused research continues to frame the next generation of cancer therapeutics.